Catalyst
Slingshot members are tracking this event:
AbbVie/Enata Hepatitis C Drug, Glecaprevir/Pibrentasvir (G/P), PDUFA Approximately 8/2/2017
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 03, 2017
Occurred Source:
https://news.abbvie.com/news/abbvie-receives-us-fda-approval-mavyret-glecaprevirpibrentasvir-for-treatment-chronic-hepatitis-c-in-all-major-genotypes-gt-1-6-in-as-short-as-8-weeks.htm
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Chronic Hepatits C, Glecaprevir, Pibrentasvir
